Who to call at REGENXBIO Inc., and when
Fundz watches for the moments REGENXBIO Inc. starts buying, and tells you who to reach.
- An alert the day REGENXBIO Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at REGENXBIO Inc., from your own LinkedIn network
REGENXBIO Inc.
The company signed a major contract or deal. An 8-K is the notice a US public company must file within four business days of a major event.
regenxbio.comAI Executive Summary
AI-powered analysis of 8-K filing content
REGENXBIO settled patent infringement litigation with Sarepta Therapeutics, University of Pennsylvania, and Catalent regarding SRP-9001/ELEVIDYS, receiving a $39 million payment that resolves ongoing disputes and protects the company's intellectual property rights.
Key Takeaways
REGENXBIO will receive $39.0 million from Sarepta within 10 days of settlement effective date
Settlement resolves patent infringement claims related to U.S. Patent Nos. 10,526,617 and 11,680,274 covering Sarepta's SRP-9001 product
2 more takeaways
Related Filings (2)
2 more filings from REGENXBIO Inc. in the last 90 days
Filing Overview
What This Means
REGENXBIO Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.